Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | $9 | $8 | $7 | $7 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $8 | $7 | $6 | $6 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.7% | 8.5% | 11.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 89.8% | 91.3% | 93% | 93.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14.6% | -22.1% | -17.1% | -14.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.5% | -15% | -10.1% | -10.5% |
| EPS Diluted | 0.56 | -0.25 | -0.16 | -0.16 |
| % Growth | 324% | -56.3% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | $0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |